Contact point of autoimmune disease and malignant tumor. On model of lymphoma of Sjoegren's syndrome.

AbstractTo evaluate the feasibility of serum HMGB1, anti-HMGB1 antibodies, and HMGB1/anti-HMGB1 ratio as a diagnosis indicator of initial clinical classification in patients with fever of unknown origin (FUO). Ninety-four patients with classical FUO and ninety healthy controls were enrolled in this study. The subjects’ clinical data and serum were collected. The serum concentration of HMGB1 was detected by a commercial HMGB1 ELISA kit, while the serum concentration of anti-HMGB1 antibodies were detected by an in-house built anti-HMGB1 antibodies ELISA kit and further confirmed by immunoblotting. According to the hospital diagnosis on discharge, ninety-four FUO patients were divided into four groups, Infectious disease subgroup, autoimmune disease subgroup, malignant tumor subgroup, and undetermined subgroup. The concentrations of HMGB1 in the infectious disease subgroup and autoimmune disease subgroup were higher than those in the malignant tumor subgroup, undetermined subgroup, and healthy control group. The concentration of anti-HMGB1 antibodies in autoimmune disease subtype group was higher than those in other subgroups as well as healthy control group. According to the distribution of HMGB1 and anti-HMGB1 in scatter plots of the patients with FUO, we found that the ratio of serum HMGB1/anti-HMGB1 is an ideal clinical indicator for differential diagnosis of different subtypes of FUO. The best cut-off was 0.75, and the sensitivity, specificity, and AUC were 66.67%, 87.32%, and 0.8, respectively. Correlation analysis showed that serum concentration of HMGB1 was moderately correlated with CRP in infectious diseases subgroup, and the serum concentration of anti-HMGB1 antibodies was strongly correlated with erythrocyte sedimentation rate in autoimmune disease subgroup. Our study had showed that serum HMGB1/anti-HMGB1 antibodies ratio can help clinicians identify FUO subtypes, thereby avoiding many unnecessary examinations and tests, and improving the effectiveness of clinical diagnosis and treatment of FUO.

Download Full-text

Hashimoto‘s thyroiditis

10.33699/pis.2021.100.3.110-112 ◽

2021 ◽

Vol 100 (3) ◽

Keyword(s):

Autoimmune Disease ◽

Thyroid Gland ◽

Malignant Tumor ◽

Lymphocytic Infiltration ◽

Conservative Surgery ◽

Hashimoto Thyroiditis ◽

Mechanical Compression ◽

Iodine Supplementation ◽

Large Goiter ◽

Organ Specific

Hashimoto thyroiditis is a chronic organ-specific autoimmune disease. It is characterized by the production of autoantibodies against thyroid gland antigens with lymphocytic infiltration of the gland, leading to gradual destruction of a functional parenchyma. The disease is a leading cause of hypothyreosis in the areas with sufficient iodine supplementation. Etiology is currently unknown, occurence of other autoimmune diseases is common and familiar occurence was noted. The disease is associated with higher risk of thyroid gland malignancy. The treatment is usually conservative, surgery is indicated in suspicion for malignant tumor or in cases of a large goiter with mechanical compression.

Download Full-text

Disease state and treatments for autoimmune disease. 1. Disease state of autoimmune disease From recent knowledge. 1) Specific control of Sjoegren's syndrome.

Nihon Naika Gakkai Zasshi ◽

10.2169/naika.87.1717 ◽

1998 ◽

Vol 87 (9) ◽

pp. 1717-1723

Author(s):

TAKAYUKI SUMIDA

Keyword(s):

Autoimmune Disease ◽

Disease State ◽

Sjoegren’S Syndrome ◽

Specific Control

Download Full-text

IFI16 and Anti-IFI16 as Novel Biomarkers for Sjoegren’s Syndrome: Preliminary Data

Proceedings ◽

10.3390/proceedings2019035030 ◽

2019 ◽

Vol 35 (1) ◽

pp. 30

Author(s):

Sonia Marino ◽

Roberta Gualtierotti ◽

Valeria Caneparo ◽

Marco De Andrea ◽

Marisa Gariglio ◽

...

Keyword(s):

Autoimmune Disease ◽

Preliminary Data ◽

Sjoegren’S Syndrome ◽

Novel Biomarkers ◽

Chronic Autoimmune Disease

Sjoegren’s syndrome (SS) is a chronic autoimmune disease characterized. [...]

Download Full-text

Hepatocyte ultrastructural alterations in perimetastatic areas

Proceedings, annual meeting, Electron Microscopy Society of America ◽

10.1017/s0424820100166300 ◽

1996 ◽

Vol 54 ◽

pp. 768-769

Author(s):

H. J. Finol ◽

M. E. Correa ◽

L.A. Sosa ◽

A. Márquez ◽

N.L. Díaz

Keyword(s):

Malignant Tumor ◽

Malignant Tumors ◽

Surrounding Tissue ◽

Ultrastructural Changes ◽

Pancreas Carcinoma ◽

Duct Carcinoma ◽

Tissue Samples ◽

Primary Malignant Tumor ◽

Transmission Electron ◽

Remote Sites

In classical oncological literature two mechanisms for tissue aggression in patients with cancer have been described. The first is the progressive invasion, infiltration and destruction of tissues surrounding primary malignant tumor or their metastases; the other includes alterations produced in remote sites that are not directly affected by any focus of disease, the so called paraneoplastic phenomenon. The non-invaded tissue which surrounds a primary malignant tumor or its metastases has been usually considered a normal tissue . In this work we describe the ultrastructural changes observed in hepatocytes located next to metastases from diverse malignant tumors.Hepatic biopsies were obtained surgically in patients with different malignant tumors which metatastized in liver. Biopsies included tumor mass, the zone of macroscopic contact between the tumor and the surrounding tissue, and the tissue adjacent to the tumor but outside the macroscopic area of infiltration. The patients (n = 5), 36–75 years old, presented different tumors including rhabdomyosarcoma, leiomyosarcoma, pancreas carcinoma, biliar duct carcinoma and colon carcinoma. Tissue samples were processed with routine techniques for transmission electron microscopy and observed in a Hitachi H-500 electron microscope.

Download Full-text

Laryngeal Manifestations of Autoimmune Diseases

Perspectives of the ASHA Special Interest Groups ◽

10.1044/2020_persp-19-00168 ◽

2020 ◽

Vol 5 (2) ◽

pp. 439-456

Author(s):

Jenny L. Pierce

Keyword(s):

Autoimmune Disease ◽

Autoimmune Diseases ◽

Patient Outcomes ◽

Correct Diagnosis ◽

Upper Airway ◽

Clinical Implications ◽

Laryngeal Function ◽

The Past ◽

Referral Practices ◽

Timely Referral

Purpose This review article provides an overview of autoimmune diseases and their effects on voice and laryngeal function. Method A literature review was conducted in PubMed. Combinations of the following keywords were used: “autoimmune disease and upper airway,” “larynx,” “cough,” “voice,” “dysphonia,” and “dyspnea.” Precedence was given to articles published in the past 10 years due to recent advances in this area and to review articles. Ultimately, 115 articles were included for review. Results Approximately 81 autoimmune diseases exist, with 18 of those highlighted in the literature as having laryngeal involvement. The general and laryngeal manifestations of these 18 are discussed in detail, in addition to the clinical implications for a laryngeal expert. Conclusions Voice, breathing, and cough symptoms may be an indication of underlying autoimmune disease. However, these symptoms are often similar to those in the general population. Appropriate differential diagnosis and timely referral practices maximize patient outcomes. Guidelines are provided to facilitate correct diagnosis when an autoimmune disease is suspected.

Download Full-text